Funded Startups in Berwyn
Among the 9 most recent funded entries tied to Berwyn, Pennsylvania, one disclosed round stands out: Advisor Credit Exchange raised $24M on 2022-07-13, and…
Among the 9 most recent funded entries tied to Berwyn, Pennsylvania, one disclosed round stands out: Advisor Credit Exchange raised $24M on 2022-07-13, and it dwarfs the next-largest disclosed amounts ($15M for Annovis Bio on 2026-05-20 and $13M for Mural Health on 2024-04-05). A second outlier is smaller in absolute terms but different in character: B Lab’s $100K grant on 2021-12-14 sits far below the $2M floor seen in the other disclosed non-undisclosed rounds.
The dataset shows a tight temporal cluster in the mid-2020s: three disclosed/dated rounds fall between 2024-04-05 (Mural Health, $13M) and 2025-06-17 (FIDx, undisclosed), with additional activity on 2026-03-03 (Persevere Therapeutics, $2M) and 2026-05-20 (Annovis Bio, $15M). Sectors also concentrate: Biotechnology appears in 3 entries (Annovis Bio in 2026-05-20 at $15M; Virpax Pharmaceuticals Inc. on 2021-09-14 at $40M; and Virpax is the only other biotech listed here). On stage disclosure, 2 of 9 rows use “Series Unknown,” and 2 of 9 rows are “undisclosed.” The round dates span 2021-09-14 to 2026-05-20, with Annovis Bio the most recent.
Most recent rounds
9 shownRelated listings
Frequently asked
What’s the largest disclosed round in Berwyn, and how does it compare to the rest of the disclosed amounts shown?
Advisor Credit Exchange’s $24M disclosed round (2022-07-13) is the top disclosed amount in these rows, and it sits well above the next-largest disclosed rounds: Annovis Bio at $15M (2026-05-20) and Mural Health at $13M (2024-04-05).
Do any sectors appear over-represented in this Berwyn list?
Biotechnology shows up in 3 of the 9 entries (Annovis Bio on 2026-05-20 for $15M; Virpax Pharmaceuticals Inc. on 2021-09-14 for $40M), with additional sectors split across Health Care, Data and Analytics, Software Development, Marketing Services, Financial Services, and Community and Lifestyle (FIDx, undisclosed; 2025-06-17).
Which entries are concentrated in the most recent part of the timeline?
Between 2026-03-03 and 2026-05-20, two entries appear: Persevere Therapeutics (Seed, $2M on 2026-03-03) and Annovis Bio (Series Unknown, $15M on 2026-05-20). The other 2025 activity is FIDx on 2025-06-17, but its amount is undisclosed.
How does disclosed stage information cluster versus “Series Unknown” and “undisclosed” outcomes?
Across 9 rows, “Series Unknown” appears in 2 entries (Annovis Bio on 2026-05-20 at $15M and 2X on 2023-03-29 with undisclosed amount), while 2 entries are explicitly “undisclosed” (FIDx on 2025-06-17 and 2X on 2023-03-29). The remaining disclosed rows carry named stage labels such as Seed, Grant, and Post-IPO Equity.
Are there outliers worth flagging beyond the largest disclosed round?
Yes. On the low end, B Lab’s $100K grant (2021-12-14) is far below the other disclosed amounts, including the $2M disclosed rounds (Persevere Therapeutics on 2026-03-03 and RISR on 2024-05-22). On the high end, Virpax Pharmaceuticals Inc.’s $40M post-IPO equity (2021-09-14) is another large disclosed figure, separated from the rest by a wide gap versus the $24M top pre-2023 disclosed amount.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.